A guide to the interpretation of serum prostate specific antigen levels

Clinical Biochemistry

Volumn 28, Issue 3, 1995, Pages 221-241

  Bunting, Peter S ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

analysis in blood; antiandrogen therapy; intraindividual variation; metabolism; prostate specific antigen; prostatic acid phosphatase; radiation therapy; radical prostatectomy; reference ranges; stage

Indexed keywords

BUSERELIN; FINASTERIDE; FLUTAMIDE; GOSERELIN; LEUPRORELIN; NAFARELIN; PROSTATE SPECIFIC ANTIGEN;

AMINO ACID ANALYSIS; HUMAN; IMMUNOASSAY; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN METABOLISM; PROTEIN STRUCTURE; REVIEW; TRANSURETHRAL RESECTION; ULTRASOUND;

HUMAN; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC DISEASES;

EID: 0029144616     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/0009-9120(95)91342-Z     Document Type: Review

References (176)

1. Prostatic tumor markers
2. Prostate specific antigen: A critical assessment of the most useful tumor marker for adenocarcinoma of the prostate
3. Prostate-specific antigen: Biochemistry, analytical methods, and clinical application
4. How to use prostate-specific antigen
5. An evaluation of prostate-specific antigen as a screening test for prostate cancer
6. Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening
7. Optimized strategy for detection of early stage, curable prostate cancer: Role of prescreening with prostate-specific antigen
8. Prostate cancer screening: What we know and what we need to know
9. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: Results of a multicenter clinical trial of 6,630 men
10. Screening for prostate cancer: A decision analytic view
11. Prostate-specific antigenic domain of human prostate specific antigen identified with monoclonal antibodies
12. Human prostate-specific antigen: Structural and functional similarity with serine proteases
13. Human prostate-specific antigen is a member of the glandular kallikrein gene family at 19q13
14. Demonstration of the role of prostate-specific antigen in semen liquefaction by two-dimensional electrophoresis
15. Structure and function of prostatic- and seminal vesicle-secreted proteins involved in the gelation and liquefaction of human semen
16. Adnexal gland secretion markers in unexplained asthenozoospermia
17. Clinical behavior of prostatic specific antigen and prostatic acid phosphatase: A comparative study
18. Sustained, substantially increased concentration of prostate-specific antigen in the absence of prostatic malignant disease: An unusual clinical scenario
19. Extraprostatic localization of prostatic acid phosphatase and prostatespecific antigen: Distribution in cloacogenic glandular epithelium and sex-dependent expression in human anal gland
20. An analysis of urinary prostate specific antigen before and after radical prostatectomy: Evidence for secretion of prostate specific antigen by the periurethral glands
21. The “female prostate”: Location, morphology, immunohistochemical characteristics and significance
22. Prostate-specific antigen and the female prostate
23. Prostate marker immunoreactivity in salivary gland neoplasms A rare pitfall in immunohistochemistry
24. Immunoreactive prostate-specific antigen levels in female and male breast tumors and its association with steroid hormone receptors and patient age
25. Carcinoembryonic antigen
26. CA-125 concentrations in malignant and nonmalignant disease (case conference)
27. Tumor markers in patients with chronic renal failure
28. Serum prostatic acid phosphatase, gamma-seminoprotein and prostatic specific antigen in hemodialysis patients
29. Effects of hemodialysis on prostate-specific antigen
30. Abrupt changes in prostate-specific antigen concentration in acute renal failure (letter)
31. Abrupt changes in the concentrations of five prostatic tumor-associated markers in serum after acute myocardial infarction (letter)
32. Prognostic implications of disappearance rate of biologic markers following radical prostatectomy
33. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate
34. Prostate specific antigen in the preoperative and postoperative evaluation of localized prostatic cancer treated with radical prostatectomy
35. Biological half-life of prostate-specific antigen after radical prostatectomy
36. Prostate-specific antigen: Establishment of the reference range for the clinically normal prostate gland and the effect of digital rectal examination, ejaculation, and time on serum concentrations
37. Effect of digital rectal examination (and ejaculation) on serum prostate-specific antigen after twenty-four hours
38. The impact of ejaculation on serum prostate specific antigen
39. Comparison of a polyclonal and monoclonal immunoassay for PSA: Need for an international antigen standard
40. Differences in values obtained with two assays of prostate specific antigen
41. Prostate-specific antigen as a marker for prostatic cancer: A monoclonal and a polyclonal immunoassay compared
42. Endogenous antibody to prostate-specific antigen in women
43. Measurement of prostate-specific antigen in serum using four different immunoassays
44. Prostate-specific antigen: Problems in analysis
45. Complex formation between protein C inhibitor and prostate-specific antigen in vitro and in human semen
46. A quantitative ELISA for the measurement of complexes of prostate-specific antigen with protein C inhibitor when using a purified standard
47. Prostate-specific antigen in serum occurs predominantly in complex with alpha1-antichymotrypsin
48. Multiple forms of prostate-specific antigen in serum: Differences in immunorecognition by monoclonal and polyclonal assays
49. Double-label time-resolved immunofluorimetric assay of prostate-specific antigen and of its complex with alpha-1 antichymotrypsin
50. Production of alpha-1-antichymotrypsin by PSA-containing cells of human prostate epithelium
51. Prostate specific antigen predominantly forms a complex with alpha-1 antichymotrypsin in blood. Implications for procedures to measure prostate specific antigen in serum
52. 1-antigen in serum of patients with prostate cancer: Assay of the complex improves clinical sensitivity for cancer
53. Method-to-method and lot-to-lot variation in assays for prostate-specific antigen
54. Disagreement between the Roche Cobas Core and Hybritech Tandem E PSA assays when measuring free, complexed and total serum prostate specific antigen
55. False positive prostate-specific antigen values in the sera of women with renal cell carcinoma
56. Re: False positive prostate-specific antigen values in the sera of women with renal cell carcinoma
57. Prostate specific antigen: immunoreactivity in urachal remnants
58. Re: Prostate specific antigen: immunoreactivity in urachal remnants
59. Elevated prostate markers in metastatic small cell carcinoma of unknown primary
60. Primary renal carcinoid. Case report and literature review
61. Immunocytochemical detection of prostate-specific antigen (PSA) in skin adnxal and breast tissues and tumors
62. The hook effect: High concentrations of prostate-specific antigen giving artifactually low values on one-step immunoassay
63. Extremely high values of prostate-specific antigen in patients with adenocarcinoma of the prostate; demonstration of the hook effect
64. More on hook effects in immunometric assays for prostate-specific antigen
65. More on hook effects in immunometric assays for prostate-specific antigen
66. Analytical and physiological characteristics of prostate-specific antigen and prostatic acid phosphatase in serum compared
67. Storage conditions for serum for estimating prostate-specific antigen
68. Consistency of a dual-monoclonal PSA assay and its clinical importance
69. The effect of digital rectal examination on serum levels of prostate-specific antigen
70. Digital rectal examination-associated alterations in serum prostate-specific antigen
71. The effect of digital rectal examination on prostate specific antigen levels
72. Effect of digital rectal examination on serum concentration of prostate-specific antigen
73. Changes in prostate-specific antigen and prostatic acid phosphatase concentration following prostatic examination in benign prostatic hypertrophy and prostate cancer patients
74. The effect of digital rectal examination on the serum prostate specific antigen concentration: Results of a randomized study
75. Effects of rectal examination, prostatic massage, ultrasonography and needle biopsy on serum prostate specific antigen levels
76. Effect of digital rectal examination on prostate specific antigen in men with prostate cancer, prostatitis, and benign prostatic hypertrophy
77. Digital rectal examination does not increase serum concentrations of prostate-specific antigen
78. Serum prostate specific antigen: In vitro stability and the effect of ultrasound rectal examination in vivo
79. Effect of cystoscopy, prostate biopsy and transurethral resection of prostate on serum prostate-specific antigen concentration
80. The effects of transurethral prostatectomy on serum prostate specific antigen
81. Measurement of prostate-specific antigen and prostatic acid phosphatase concentrations in serum before and 1–42 days after transurethral resection of the prostate and orchidectomy
82. Observations on the doubling time of prostate cancer. The use of serial prostate-specific antigen in patients with untreated disease as a measure of increasing cancer volume
83. The importance of imprecision
84. Evaluation of the Abbott IMx automated immunoassay of prostate-specific antigen
85. Abbott IMx evaluated for assay of prostate-specific antigen in serum
86. Analytical performance goals for measuring prostate-specific antigen
87. Spontaneous circadian fluctuations of prostate specific antigen and prostatic acid phosphatase serum activities in patients with prostatic cancer
88. Daily variability in human serum prostate-specific antigen and prostatic acid phosphatase: A comparative evaluation
89. Serum prostate-specific antigen: Hourly change/24 hours compared with prostatic acid phosphatase
90. Relationship between diurnal rhythm of serum testosterone and two prostatic markers (PSA and PAP) in untreated prostate cancer
91. Measurement of serum PSA using IMx prostate specific antigen assay
92. Unpredictable fluctuations in serum acid phosphatase activity in prostatic cancer
93. Circadian and day-to-day variations of prostatic acid phosphatase
94. The role of serum PAP as a tumor marker in men with adbanced adenocarcinoma of the prostate
95. Quantitation of prostate-specific antigen in serum by a sensitive enzyme immunoassay
96. Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges
97. The value of serum prostate specific antigen determinations before and after radical prostatectomy
98. Prostate specific antigen and local recurrence after radical prostatectomy
99. Prognostic implications of disappearance rate of biologic markers following radical prostatectomy
100. Prostate specific antigen levels after post radical prostatectomy in patients with organ confined and locally extensive prostate cancer
101. Detection of local recurrence after radical prostatectomy by prostate specific antigen and transrectal ultrasound
102. The value of prostate specific antigen and transrectal ultrasound-guided biopsy in accurately detecting prostatic fossa recurrences following radical prostatectomy
103. Prostate specific antigen in screening for recurrence following radical prostatectomy for localised prostatic cancer
104. The enhanced detection of persistent disease after radical prostatectomy with a new prostate specific antigen immunoassay
105. Ultrasensitive time-resolved immunofluorometric assay of prostate-specific antigen in serum and preliminary clinical studies
106. Modified assay of prostate-specific antigen with a detection limit <0.01 μg/L
107. Changes in prostate-specific markers under chronic gonadotrophin-releasing hormone analogue treatment of stage D prostate cancer
108. Biochemical monitoring of cancer of the prostate treated with an LH-RH analogue
109. Prostate specific antigen and prostatic acid phosphatase for monitoring therapy of cancer of the prostate
110. Hormone therapy prior to radical prostatectomy in patients with clinical stage C prostate cancer
111. Prostate specific antigen decline after antiandrogen withdrawal: The flutamide withdrawal syndrome
112. Metastatic prostate cancer pulmonary nodules: Beneficial effects of combination therapy and subsequent withdrawal of flutamide
113. Effect of finasteride on serum PSA concentration in men with benign prostatic hyperplasia. Results from the North American Phase III Clinical Trial
114. Clinical experience of the detection of prostate cancer in patients with BPH treated with finasteride
115. Serum PSA after antiandrogen therapy
116. Prostate specific antigen in hormonally treated stage D2 prostate cancer: Is it always an accurate indicator of disease status?
117. Steroids inversely affect the biosynthesis and secretion of human prostatic acid phosphatase and prostate-specific antigen in the LN-CaP cell line
118. Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. IV. Anti-androgen treated patients
119. Clinical use of prostate specific antigen in patients with prostate cancer
120. Prognostic significance of prostate specific antigen in endocrine treatment for prostatic cancer
121. The clinical usefulness of serum prostate-specific antigen after hormonal therapy of metastatic prostate cancer
122. Prognostic significance of changes in prostate-specific markers after endocrine treatment of stage D2 prostate cancer
123. Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer
124. Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer
125. Early androgen ablation for stage D1 (N1 to N3, MO) prostate cancer: prognostic variables and outcome
126. Role of prostate-specific antigen as a predictor of outcome in prostate cancer
127. Prostate-specific antigen decline after casodex withdrawal: Evidence for an antiandrogen withdrawal syndrome
128. Endocrine therapies for symptomatic benign prostatic hyperplasia
129. Serum PSA as a tumor marker for patients undergoing definitive radiation therapy
130. Prostate-specific antigen as a predictor of radiotherapy response and patterns of failure in localized prostate cancer
131. Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. III. Radiation treated patients
132. Identification of residual cancer in the prostate following radiation therapy: Role of transrectal ultrasound guided biopsy and prostate specific antigen
133. Prostate specific antigen as an indicator of response to radiotherapy in prostate cancer
134. Prostate specific antigen in the management of patients with localized adenocarcinoma of the prostate treated with primary radiation therapy
135. Prostate-specific antigen and external beam radiation therapy in prostate cancer
136. Biopsy after external beam radiation therapy for adenocarcinoma of the prostate: Correlation with original histological trade and current PSA levels
137. Prostate-specific antigen; an important marker for prostate cancer treated by external radiotherapy
138. Prostate specific antigen after external beam radiation therapy for prostate cancer: Follow-up
139. Prostate specific antigen after definitive radiotherapy for clinically localized prostate cancer
140. Radical radiation therapy in the management of prostate adenocarcinoma: The initial PSA value as a predictor of treatment outcome
141. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer
142. The use of prostate-specific antigen in staging patients with newly diagnosed prostate cancer
143. Predicting radionuclide bone scan findings in patients with newly diagnosed untreated prostate cancer: Prostate specific antigen is superior to all other clinical parameters
144. Levels of prostate specific antigen that predict skeletal spread in prostate cancer
145. Ability of preoperative serum prostate-specific antigen value to predict pathologic stage and DNA ploidy. Influence of clinical stage and tumor grade
146. Utility of pre-operative serum prostate-specific antigen concentration and biopsy Gleason score in predicting risk of pelvic lymph node metastasis in prostate cancer
147. Prostate specific antigen and Gleason grade: An immunohistochemical study of prostate cancer
148. Estimation of prostatic growth serial prostate-specific antigen measurements in men with and without prostate disease
149. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease
150. Observations on the doubling time of prostate cancer. The use of serial prostate-specific antigen in patients with untreated disease as a measure of increasing cancer volume
151. Relationship between changes in prostate-specific antigen and prognosis of prostate cancer
152. Prostate specific antigen density: A means of distinguishing benign prostatic hypertrophy and prostate cancer
153. The use of prostate specific antigen density to enhance the predictive value of intermediate levels of serum prostate specific antigen
154. Correlation between prostate-specific antigen and prostate volume, evaluated by transrectal ultrasonography: Usefulness in diagnosis of prostate cancer
155. Determination of prostate volume with transrectal US for cancer screening. Part K. Comparison with prostate-specific antigen assays
156. Prostate-specific antigen and the prostate gland volume: Correlation and clinical application
157. The use of prostate specific antigen and prostate specific antigen density in the diagnosis of prostate cancer in a community based urology practice
158. Prospective evaluation of prostate-specific antigen density and systematic biopsies for early detection of prostate carcinoma
159. The inability of prostate specific antigen index to enhance the predictive value of prostate specific antigen in the diagnosis of prostatic carcinoma
160. Prostate specific antigen in the staging of localized prostate cancer: Influence of tumor differentiation, tumor volume and benign hyperplasia
161. Changes in prostate-specific markers under chronic gonadotrophin-releasing hormone analogue treatment of stage D prostatic cancer
162. Clinical behavior of prostatic specific antigen and prostatic acid phosphatase: A comparative study
163. Prostate specific antigen and prostatic acid phosphatase measurements for the follow-up of patients with prostate cancer
164. Relative value of prostate-specific antigen and prostatic acid phosphatase in diagnosis and management of adenocarcinoma of prostate. Ohio State University experience
165. Prostate specific antigen and prostatic acid phosphatase for monitoring therapy of cancer of the prostate
166. Editorial
167. A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer
168. Selection of optimal prostate specific antigen cutoffs for early detection of prostate cancer: Receiver operating characteristic curves
169. Relative sensitivity and specificity of serum prostate specific antigen (PSA) level compared with age-referenced PSA, PSA density, and PSA change
170. SR1 assays of α-fetoprotein, carcinoembryonic antigen and prostate-specific antigen compared wit corresponding established commercial assays
171. The effects of exercise and activity on serum prostate specific antigen levels
172. Nontraumatic elevation of prostate specific antigen following cardiac surgery and extracorporeal cardiopulmonary bypass
173. Preanalytical and biological variability of prostatic acid phosphatase and prostate-specific antigen in serum from patients with prostatic pathology